Skip to content
Navigate to homepage - Cerba Research
Resource Library

White paper – Lessons Learned: 10 Best Practices in Clinical Trial Operations for Virology Studies

At Cerba Research, we’ve harnessed over 35 years of unparalleled expertise in handling logistical clinical trials. Our robust logistics infrastructure is the cornerstone of swift and secure transportation, ensuring the seamless journey of delicate virological and PBMC samples from patients to laboratories.

In the whitepaper “10 Best Practices in Clinical Trial Operations for Virology Studies.”  we dive into the world of cutting-edge strategies and expert insights in clinical trial operations for virology studies from a practical point of view.

Key Topics Covered:

🔍 ROI and Clinical Trial Operations Management: Discover how optimizing operations can drive remarkable returns on investment, enhancing the success of your virology studies.

📊 Clinical Trial Operations KPIs: Delve into the metrics that truly matter, gaining insights into monitoring and measuring success effectively.

⚖️ Capacity and Demand Differences: Learn how to navigate the dynamic balance between capacity and demand to ensure your trials stay on track.

📚 Training & Knowledge Sharing in the Supply Chain: Elevate your supply chain with strategies for fostering knowledge sharing and empowering your team.

💡 Process Optimization: Streamline your operations for maximum efficiency, minimizing delays and maximizing outcomes.

🔗 Data Management in Clinical Trials: Master the art of data handling and management, a critical component of successful virology studies.

And much more! Complete the form below to download the white paper now!

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Contact Us
Resource Library

White paper – Logistics for Cell & Gene Therapy Trials: Specific Needs Demands Special Skills

The rapid increase in cell and gene therapies holds unprecedented potential. However, great innovations come with great responsibilities, especially when it comes to clinical trial logistics. Mistakes in this process can be more than just harmful – they can be costly for sponsors and, even more importantly, pose risks to patient.

The whitepaper ‘‘Logistics for Cell & Gene Therapy Trials: Specific Needs Demands Special Skills” takes you through the unique challenges of cell & gene therapy trials logistics. We shed light on potential issues and emphasize the crucial role of careful planning and execution.

📚 Key Highlights in The Whitepaper:

⚙️ Complex Logistics Unraveled: Understand the intricate logistics of Cell & Gene Therapy Trials – where precision is key.

🔬 Cerba’s Real Case Study: Join us as we tackle logistics challenges in a groundbreaking viral vector-based therapy for Spinal Muscular Atrophy (SMA). Learn from real experiences.

🌐 Experts Who Understand: Discover why specialized expertise matters for successful Cell & Gene Therapy Trials logistics.

🗺️ Managing Across Locations: Learn to efficiently handle logistics across different places while ensuring therapy integrity.

📜 Navigating Regulations: Get insights into the rules that guide these therapies and shape logistics decisions.

📊 Handling Data Right: Explore strategies for accurate, secure, and compliant data management.

 

Complete the form below to download the white papers!
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Contact Us
Resource Library

Nonnegotiable Central Laboratory Capabilities for I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next generation sequencing.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts & discover how we can help you transform research and advance health

Contact Us
Resource Library

Webinar: Turning Precision Medicine into Action in Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Resource Library

Presence and Capabilities – Running Clinical Trials in Australia Infographic

With Cerba’s network spanning five continents, team up with our experienced scientists to generate early insights and direct the course of your complex trial.

Our locations consist of cutting-edge laboratories that provide a full portfolio of specialty laboratory testing, anchored by seven centers in the Americas, Europe, Africa, and Asia-Pacific regions. With consistent, high-quality data and a road map to the patients you need, we empower you to develop personalized medicines and diagnostic solutions that will change lives worldwide.

Discover our Australia capabilities

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Cerba Research’s Multi-Omics Approaches in Hematological Malignancies

Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.

Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.

At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Cerba Research Biorepository Brochure

A biorepository enabled by a leading medical diagnostic and healthcare infrastructure

Since 1967, Cerba HealthCare Group has accompanied scientific and technological advances in diagnosis, prevention and precision medicine in order to better meet the expectations of health professionals and patients. This constant quest for improvement has led Cerba Research to create one of the world’ s largest and multinational commercial biorepository with the unique goal of contributing to the advancement of Science.

As a specialty and central laboratory for clinical trials covering 5 continents, our biospecimen provision is the starting point for your research to facilitate further downstream decisions inclusion: robust assay development and assay validation with quality samples.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Processing Peripheral Blood Mononuclear Cells (PBMC) For Clinical Trials

PBMC-based analytical tests are crucial to accelerating the development of new vaccines, drug discovery, diagnostic development, Precision Medicine Research (e.g., CAR-T cell therapy, gene therapy, etc.), and toxicology applications. To this end, the supply of high-quality PBMC is an essential first step in the process.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us
Resource Library

Leveraging Medical Laboratory Data for Patient Recruitment

Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow

Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.

Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhances access to data. The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.

Watch the recording of this webinar to learn more about patient recruitment for decentralized clinical trials.

Webinar – Leveraging Medical Laboratory Data for Patient Recruitment

Cerba Research - Webinar - Leveraging Medical Laboratory Data for Patient Recruitment - Thumbnail play button
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trials

Contact Us